Lilly and Haya Therapeutics Collaborate in $1 Billion Deal to Explore ‘Dark Genome’ for Obesity Treatments

Partnership:
Eli Lilly has entered into a partnership with Haya Therapeutics in a deal worth up to $1 billion to discover and develop RNA-based drug targets for obesity by exploring the 'dark genome'.

Focus:
The collaboration aims to identify regulatory-genome-derived RNA targets that could lead to novel obesity treatments.

Haya Therapeutics:
Haya is a precision medicines company that specializes in RNA-guided programmable therapeutics, focusing on long non-coding RNAs (lncRNAs) and their role in various diseases, including heart failure and solid tumor cancers.

Deal Structure:
The deal includes biobucks, which are contingent payments based on the achievement of specific milestones in drug discovery, development, and commercialization.

Objective:
The partnership seeks to leverage Haya's expertise in RNA-targeted therapeutics to uncover new targets in the 'dark genome' that could lead to more effective and safer treatments for obesity.